Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial

被引：0
|
作者：
Atkins, Michael B. [1 ]
Escudier, Bernard [2 ]
Mcdermott, David F. [3 ]
Burotto, Mauricio [4 ]
Choueiri, Toni K. [5 ,6 ]
Hammers, Hans J. [7 ]
Plimack, Elizabeth R. [8 ]
Porta, Camillo [9 ]
George, Saby [10 ]
Powles, Thomas [11 ]
Donskov, Frede [12 ,13 ]
Kollmannsberger, Christian K. [14 ]
Grimm, Marc-Oliver [15 ]
Tomita, Yoshihiko [16 ]
Rini, Brian, I [17 ]
Jiang, Ruiyun [18 ]
Federov, Viktor [18 ]
Lee, Chung-Wei [18 ]
Desilva, Heshani [18 ]
Tannir, Nizar M. [19 ]
Motzer, Robert J. [20 ]
机构：
[1] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Gustave Roussy, Villejuif, France
[3] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA
[4] Bradford Hill Clin Res Ctr, Santiago, Chile
[5] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[6] Harvard Med Sch, Boston, MA USA
[7] UT Southwestern Kidney Canc Program, Dallas, TX USA
[8] Fox Chase Canc Ctr, Oreland, PA USA
[9] Univ Pavia, Pavia, Italy
[10] Roswell Pk Canc Inst, Buffalo, NY USA
[11] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, Royal Free Natl Hlth Serv Trust, London, England
[12] Univ Hosp, Cesena, Italy
[13] Southern Denmark Univ Hosp, Vejle, Denmark
[14] British Columbia Canc Agcy, Abbotsford, BC, Canada
[15] Jena Univ Hosp, Jena, Germany
[16] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[17] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[18] Bristol Myers Squibb, Moreton, England
[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[20] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
ONCOLOGIST | 2024年 / 29卷
关键词：
Nivolumab; Ipilimumab; CheckMate; 214; Advanced RCC; Favorable Risk;
D O I：
10.1093/oncolo/oyae181.026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8
引用
收藏
页码：S17 / S18
页数：2
相关论文
共 50 条
  • [31] Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
    Rini, Brian, I
    Signoretti, Sabina
    Choueiri, Toni K.
    McDermott, David F.
    Motzer, Robert J.
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Tykodi, Scott S.
    Pal, Sumanta K.
    Gupta, Saurabh
    Lee, Chung-Wei
    Jiang, Ruiyun
    Tannir, Nizar M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (12)
  • [32] First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma A Cost-effectiveness Analysis
    Wan, XiaoMin
    Zhang, YuCong
    Tan, ChongQing
    Zeng, XiaoHui
    Peng, LiuBao
    JAMA ONCOLOGY, 2019, 5 (04) : 491 - 496
  • [33] Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.
    McDermott, David F.
    Rini, Brian I.
    Motzer, Robert J.
    Tannir, Nizar M.
    Escudier, Bernard
    Kollmannsberger, Christian K.
    Hammers, Hans J.
    Porta, Camillo
    George, Saby
    Donskov, Frede
    Gurney, Howard
    Grimm, Marc-Oliver
    Harrison, Michael Roger
    Hutson, Thomas E.
    Yang, Shuo
    Johansen, Jennifer
    Rao, Sumati
    Mekan, Sabeen Fatima
    Rael, Michael
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [34] Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
    Benjamin Duy Tran
    Jing Li
    Neang Ly
    Raffaella Faggioni
    Lorin Roskos
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 179 - 189
  • [35] First-line nivolumab plus cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
    Porta, C. G.
    Burotto, M.
    Suarez Rodriguez, C.
    Bourlon, M. T.
    Hsieh, J.
    Shah, A. Y.
    Hamzaj, A.
    Bedke, J.
    Pook, D.
    Kessler, R.
    Tomita, Y.
    Drakaki, A.
    Zhang, J.
    Simsek, B.
    Schwab, G.
    Escudier, B.
    Motzer, R. J.
    Choueiri, T. K.
    Apolo, A. B.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S688 - S689
  • [36] First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Cleary, James M.
    Elimova, Elena
    Karamouzis, Michalis
    Bruges, Ricardo
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshi
    Tehfe, Mustapha
    Zander, Thomas
    Kowalyszyn, Ruben
    Pazo-Cid, Roberto
    Schenker, Michael
    Feeny, Kynan
    Wang, Rui
    Lei, Ming
    Chen, Clara
    Nathani, Raheel
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2012 - 2020
  • [37] ASCO-GU: 2-Year Follow-up of the CheckMate-9ER Study: Sustained Treatment Benefit with First-line Therapy of advanced Renal Cell Carcinoma with Cabozantinib plus Nivolumab versus Sunitinib
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [38] Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
    Watson, Tina R.
    Gao, Xin
    Reynolds, Kerry L.
    Kong, Chung Yin
    JAMA NETWORK OPEN, 2020, 3 (10)
  • [39] Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
    Tran, Benjamin Duy
    Li, Jing
    Ly, Neang
    Faggioni, Raffaella
    Roskos, Lorin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (02) : 179 - 189
  • [40] Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
    Mantia, Charlene M.
    Jegede, Opeyemi A.
    Plimack, Elizabeth R.
    Powles, Thomas
    Motzer, Robert J.
    Tannir, Nizar M.
    Lee, Chung-Han
    Tomita, Yoshihiko
    Voss, Martin H.
    Choueiri, Toni K.
    Rini, Brian, I
    Hammers, Hans J.
    Escudier, Bernard
    Albiges, Laurence
    Rosenblatt, Lisa
    Atkins, Michael B.
    Regan, Meredith M.
    McDermott, David F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07) : 1 - 11
12345